S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
Log in
OTCMKTS:LBTSF

Almirall Stock Forecast, Price & News

$12.40
0.00 (0.00 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.40
Now: $12.40
$12.40
50-Day Range
$12.40
MA: $12.40
$12.40
52-Week Range
$10.05
Now: $12.40
$19.15
VolumeN/A
Average Volume944 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Almirall, S.A., a pharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, cutaneous T-cell lymphoma, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications; and for central nervous system, cardiovascular, and gastrointestinal diseases. Its products include Actikerall, Solaraze, Cordran Tape, Skilarence, Ilumetri, Seysara, Almax, Crestor, Provisacor, Sativex, Ebastel, Aczone, Tazorac, Azelex, and Veltin. Almirall, S.A. has a strategic research collaboration with Evotec AG to discover and develop first-in-class therapeutics in the field of dermatology diseases; collaborative research and license agreement with X-Chem, Inc. for the development of oral compounds for patients suffering from dermatological diseases; research collaboration with Iktos in the area of artificial intelligence for new drug design; multi-target research collaboration with the University of Dundee to develop novel targeted protein degraders medicines; and collaboration with Popit to provide a novel support solution for patients with psoriasis. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

MarketRank

Overall MarketRank

0.48 out of 5 stars

Medical Sector

1556th out of 1,922 stocks

Biotechnology Industry

59th out of 88 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:LBTSF
CUSIPN/A
CIKN/A
Phone34 93 291 30 00
Employees1,820
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable
$12.40
0.00 (0.00 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LBTSF News and Ratings via Email

Sign-up to receive the latest news and ratings for LBTSF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Almirall (OTCMKTS:LBTSF) Frequently Asked Questions

How has Almirall's stock been impacted by Coronavirus (COVID-19)?

Almirall's stock was trading at $13.00 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, LBTSF shares have decreased by 4.6% and is now trading at $12.40.
View which stocks have been most impacted by COVID-19
.

Is Almirall a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Almirall in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Almirall stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LBTSF, but not buy additional shares or sell existing shares.
View analyst ratings for Almirall
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Almirall?

Wall Street analysts have given Almirall a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Almirall wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Almirall?

Almirall saw a drop in short interest during the month of December. As of December 31st, there was short interest totaling 11,100 shares, a drop of 26.5% from the December 15th total of 15,100 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is presently ∞ days.
View Almirall's Short Interest
.

Who are some of Almirall's key competitors?

Who are Almirall's key executives?

Almirall's management team includes the following people:
  • Dr. Jorge Gallardo Ballart, Chairman & Pres (Age 64)
  • Mr. Peter Guenter, CEO, Chairman of Management Board & Exec. Director (Age 58)
  • Mr. Michael McClellan, Exec. VP of Fin., CFO & Member of Management Board (Age 49)
  • Mr. Joan Figueras Carreras, Gen. Counsel, Corp. Director, Vice Sec., Member of Mgmt. Board & Non-Voting Director
  • Mr. Eloi Crespo Cervera, Sr. VP of Industrial Operations & Member of Management Board
  • Mr. Alfredo Barón de Juan, Exec. VP of Global Commercial Operations & Member of Management Board
  • Dr. Francesca Domenech Wuttke Ph.D., Chief Digital Officer & Member of Management Board
  • Mr. Jordi Sabé Richer, Sr. VP of Corp. Devel. & Member of Management Board
  • Ms. Amita Kent, Sr. VP of Legal, Global Chief Compliance & Data Privacy Officer and Member of Management Board
  • Mr. Esteve Conesa Panicot, Sr. VP of HR & Member of Management Board

What is Almirall's stock symbol?

Almirall trades on the OTCMKTS under the ticker symbol "LBTSF."

How do I buy shares of Almirall?

Shares of LBTSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Almirall's stock price today?

One share of LBTSF stock can currently be purchased for approximately $12.40.

What is Almirall's official website?

The official website for Almirall is www.almirall.com.

How can I contact Almirall?

The company can be reached via phone at 34 93 291 30 00.

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.